Background: Faropenem has in vitro activity against Mycobacterium tuberculosis (Mtb) and shows synergy with rifampicin. We tested this in a whole-blood bactericidal activity (WBA) trial.
Introduction
The role of b-lactam antibiotics in the treatment of TB has been perceived to be limited as a result of their susceptibility to hydrolysis by Mycobacterium tuberculosis (Mtb) b-lactamase and their poor permeability across the mycobacterial cell wall. 1 Nevertheless, the b-lactams amoxicillin, imipenem and meropenem (administered with clavulanic acid, a b-lactamase inhibitor) are included in WHO guidelines for treatment of drug-resistant TB, albeit to be used only when it is not otherwise possible to construct a regimen using at least five active drugs. 2 Faropenem is an orally administered b-lactam antibiotic, structurally similar to the carbapenems but with a sulphur atom substitution that gives it a unique profile in terms of stability and efficacy, and permits oral dosing. 3, 4 It has been licensed in a number of countries for the treatment of infections of the lower respiratory tract, ear, nose, throat or genito-urinary system. 5, 6 Recent in vitro studies indicate that faropenem has substantial bactericidal activity against Mtb (superior to carbapenems), is active against all strains of Mtb, including resistant isolates, has intrinsic resistance to hydrolysis by b-lactamase and displays synergistic activity with rifampicin. 7, 8 It therefore appears to be a promising candidate for further investigation in TB clinical trials, with potential utility both for MDR TB and also for drug-susceptible TB (where, in the latter case, synergy with rifampicin might permit treatment shortening).
We set out to assess the bactericidal activity of faropenem (administered with amoxicillin/clavulanic acid) alone and in combination with rifampicin in a whole-blood bactericidal activity (WBA) assay, a clinical experimental paradigm for the initial evaluation of TB drugs that has been shown to relate to results of early bactericidal activity (EBA) studies as well as rates of culture sterilization in Phase 2b clinical trials. 9 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Methods

Ethics and regulatory approvals
The study was conducted in accordance with the Declaration of Helsinki. The protocol received ethics approval (2014/00729) from the National Healthcare Group's Domain Specific Review Board (NHG-DSRB) in Singapore and regulatory approval (CTC1400536) from the Health Sciences Authority (HSA), Singapore. All participants provided written informed consent. The study is registered in ClinicalTrials.gov (NCT02393586).
Study design
Participants were recruited over a period of 3 months (August to October 2015) from a database of healthy volunteers. Participants were required to be over the age of 21, without: concurrent signs of active TB; previous hypersensitivity or allergy to rifampicin or b-lactam drugs; current use of drugs with known interactions with any of the study drugs; use of drugs or herbal preparations known to affect cytochrome P450 enzymes; serum creatinine level or liver enzyme activity above the upper limit of normal; current alcohol abuse; or known hepatic disease.
Randomization was performed with opaque envelopes. These were pre-prepared, each containing a code for one of three study groups (in a ratio consistent with the desired final group sizes; see the 'Sample size and statistical analysis' section), and then numbered in a random order using a web-based random number generator (www.randomizer.org). To randomize a participant, the research nurse (who was not aware of the code list) opened the next numbered envelope in the sequence. The randomized treatment assignments were: (i) faropenem (600 mg) plus amoxicillin/clavulanic acid (500/125 mg); (ii) rifampicin (10 mg/kg, rounded up to the nearest 150 mg); and (iii) rifampicin plus faropenem plus amoxicillin/clavulanic acid (doses as above).
Faropenem was administered as three 200 mg tablets (Farobact, Cipla, Mumbai). Amoxicillin/clavulanic acid was administered as a single 625 mg tablet (Augmentin, GlaxoSmithKline, Ireland), for potential synergy with faropenem. Rifampicin was administered as 300 mg tablets (Rifaren, Remedica Ltd, Cyprus) and, if required for rounding up purposes, a single 150 mg tablet (Rifaren, Remedica Ltd, Cyprus). All study drugs were administered orally as a single dose after a meal. Treatment was open label.
Blood samples were collected at baseline (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6 and 8 h post-dose. For pharmacokinetic (PK) determinations, plasma was separated as soon as possible (within 30 min) from the blood samples and stored at #20 C. For WBA assays, blood samples were kept at room temperature with slow constant shaking until transfer to the BSL3 laboratory for set-up of cultures (within a maximum of 8 h from sample collection). Laboratory staff performing the PK and WBA assays were blinded to the treatment allocations.
Analytical methods
Faropenem, rifampicin (Toronto Research Chemicals Inc., Ontario, Canada) and amoxicillin (Sigma Chemical Co., St Louis, MO, USA) levels in plasma were measured using LC-MS/MS. Calibration samples of faropenem (0.1-20 mg/L), amoxicillin (0.1-20 mg/L) and rifampicin (0.2-40 mg/L) in plasma were prepared by adding stock solutions of the drugs in blank plasma followed by serial dilution. Analytes were extracted from each sample by protein precipitation using methanol before injecting into the LC-MS/MS system. The LC-MS/MS system consisted of an Agilent 1290 UHPLC equipped with a cooled autosampler (6 C) connected to an Agilent 6490 triple quadrupole mass spectrometer (Agilent Technologies, Waldbronn, Germany). Chromatographic separations were achieved using a Zorbax Eclipse Plus C18 column (Agilent, 50 mm % 2.1 mm, 1.8 lm) with gradient elution. The mass spectrometer was operated under positive ionization mode and the detection of faropenem, amoxicillin and rifampicin was based on multiple-reaction monitoring of 308!178, 366!349 and 823!791 m/z, respectively.
PK analyses
PK parameters were estimated by a model-independent method. The area under the plasma concentration versus time curve from 0 to the last sampling time, 8 h post-dosing (AUC last ), was calculated according to the linear up/log down trapezoidal rule (Phoenix WinNonlin, Pharsight, CA, USA). The terminal half-life (t 1/2 ) in plasma was calculated from the elimination rate constant (k e ), estimated as the slope of the log-linear terminal portion of the mean plasma concentration versus time curve, by linear regression analysis.
WBA assay
The WBA assay was based on a previously described method. 9 In brief, Mtb
H37Rv was grown in 7H9 medium to mid-log phase and then frozen in 10% glycerol aliquots of OD 1.0 at #80 C to be used as standard stock for all subsequent experiments. A standard curve relating the time to positivity (TTP) in culture to the volume of the stock was generated by performing serial 5-fold dilutions of the stock (from 25 to 25%10
#8 lL) in 7H9 medium, inoculating into Mycobacterial Growth Indicator Tubes (MGITs) in duplicate and incubating in the MGIT960 detection system (Becton Dickinson, Franklin Lakes, USA). TTP was recorded to the nearest minute.
WBA cultures were set up from each of the participants' blood samples by inoculating 300 lL of heparinized blood with 0.5 lL of mycobacterial stock (the volume estimated from the standard curve that would yield a TTP of 5.5 days) and topping up with sufficient tissue culture medium (RPMI 1640 with GlutaMAX TM Supplement and 25 mmol/L HEPES) to make up a total culture volume of 600 lL. Cultures were set up in sealed screw-cap tubes, which were incubated at 37 C with slow constant mixing for 72 h. At the end of the incubation period, cultures were centrifuged at 12000 rpm for 5 min and the liquid phase was removed. Blood cells were lysed by adding 1 mL of sterile water to the pellet and vortexing over a 10 min period. Samples were centrifuged again at 12000 rpm for 10 min and the supernatant was discarded. The pellet was re-suspended in 500 lL of 7H9 medium and inoculated into MGIT tubes, and the TTP was recorded. WBA cultures were set up in duplicate at every timepoint and the mean TTP was calculated. Control cultures were set up on the day of WBA set-up, also in duplicate, by inoculating the standard volume of the stock directly into MGIT tubes. The WBA at each of the individual sample timepoints was obtained from the difference between the log of the volume on the standard curve that corresponded to the TTP for that timepoint and the log of the volume corresponding to the TTP of the control culture. This is equivalent to the difference in log of bacterial cfu between the sample and the control, reported as Dlog cfu.
Additional experiments Drug stability in whole blood
Stability of the study drugs in whole blood was determined on blood samples taken at the 2 h post-dose timepoint (predicted to approximate the C max ) in eight participants across the three groups (three from the faropenem ! amoxicillin/clavulanic acid group, two from the rifampicin group and three from the rifampicin ! faropenem ! amoxicillin/clavulanic acid group). Samples were incubated under identical conditions to the WBA cultures (but without addition of bacterial stock or RPMI) and aliquots were removed at 24, 48 and 72 h. Plasma was separated and stored at #20 C, and drug levels were analysed as described for PK studies above.
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WBA cultures with supplementary faropenem
We tested the effects of more sustained levels of faropenem throughout the 72 h period of WBA culture using blood samples from a group of healthy volunteers not participating in the main study. WBA cultures were set up as described above by incubating 300 lL of whole blood with the standard volume of Mtb H37Rv stock, and made up to a total culture volume of 600 lL with RPMI to which faropenem was added to achieve a final concentration of 5 mg/L (approximating the mean C max measured in plasma). After 24 and 48 h of incubation, supplementary faropenem was added to the cultures to restore the concentration to at least 5 mg/L. At the end of 72 h, Mtb was recovered from the whole-blood cultures, inoculated in MGIT and the TTP measured, as described above (WBA was calculated from the mean of three experiments).
Determination of MIC 90 and MBC 99
MIC was determined in a 96-well plate format using Middlebrook 7H9 growth medium. 10 Briefly, log-phase Mtb H37Rv cultures (OD 600 0.4-0.6) were diluted to an OD 600 of 0.1, 100 lL of which was added to each well of the 96-well plate already containing 100 lL of serially diluted faropenem (alone or in combination with a fixed concentration of clavulanic acid) at 2% the final required concentrations. Plates were incubated for 1 week at 37 C with shaking at 80 rpm, at the end of which the contents of all wells were resuspended to obtain uniform turbidity. Absorbance (OD 600 ) was measured using the Tecan plate reader and MIC 90 was obtained from the absorbance-concentration curve. For MBC determination, cultures of Mtb H37Rv (OD 0.05) were incubated with 2-fold serial dilutions of faropenem (range 5-80 mg/L) for 7 days, after which 25 lL of varying dilutions of Mtb H37Rv culture from each drug dilution were plated onto duplicate Middlebrook 7H10 plates to determine cfu. 7H10 plates were incubated at 37 C for 3-4 weeks until colonies appeared and MBC 99 was calculated (concentration producing 2 log 10 reduction from initial cfu).
Sample size and statistical analysis
To determine the sample size for assessing bactericidal activity of faropenem, we assumed the cumulative WBA at 8 h (the primary outcome) would be #0.1 Dlog cfu in the faropenem ! amoxicillin/clavulanic acid group with a standard deviation of 0.1 Dlog cfu, based on previously published data for another experimental TB drug tested in this paradigm. 11 A sample size of eight in the faropenem ! amoxicillin/clavulanic acid group would give 88% power to reject the hypothesis that the cumulative WBA of faropenem ! amoxicillin/clavulanic acid is zero, with a of 0.05 using a onesided, one-sample t-test. To determine the sample size for assessing whether faropenem has additive or synergistic activity with rifampicin, we assumed a mean difference in cumulative WBA of #0.1 Dlog cfu and SD of 0.1 Dlog cfu for both the rifampicin ! faropenem ! amoxicillin/clavulanic acid and the rifampicin group. A sample size of 14 per group would give 84% power to reject the hypothesis that rifampicin ! faropenem ! amoxicillin/clavulanic acid had no additional WBA activity compared with rifampicin alone, with a of 0.05 using a one-sided t-test.
PK parameters were compared between groups using a two-sided, twosample t-test (log-transformed C max , log-transformed AUC last , t 1/2 ) or Mann-Whitney U-test (T max ).
Individual WBA values were expressed as the total bacterial killing over the 72 h of the assay. Maximum WBA for each participant was the maximum of the individual WBA values obtained at any timepoint up to 8 h post-dose. The cumulative WBA was calculated for each participant from the area under the curve of the individual WBA values measured up to that timepoint, determined using the trapezoidal method. 12 For the purposes of this calculation, the individual WBA values were converted to a rate of kill per hour (assuming that the rate of kill was constant over the 72 h period of each WBA culture). The time factors cancel in the calculation of AUC, so the cumulative WBA is expressed as absolute kill by the specified timepoint after dosing.
For analysis of bactericidal activity in the faropenem ! amoxicillin/clavulanic acid group, the cumulative WBA at 8 h post-dose and the maximum WBA during the 8 h post-dose interval were each compared with zero using a one-sided, one-sample t-test. The relationship between WBA and faropenem plasma concentration at all sample timepoints at which both parameters were measured in this group was tested by a linear mixed model with random intercepts and the slope of the regression line compared with zero with a t-test.
For comparison of the bactericidal activity in the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups, the maximum WBA and cumulative WBA over the interval to 8 h post-dose were compared between groups using a one-sided t-test (with a supplementary analysis comparing the groups on the cumulative WBA over the interval to 1 h postdose). The relationship between rifampicin plasma concentration and WBA in the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups was determined separately for each group by non-linear mixed modelling with random intercepts performed using a four-parameter equation to describe a sigmoid curve and equation parameters were fitted to observed values by iterative methods using SAS (further details are provided in Supplementary Methods, available as Supplementary data at JAC Online). The curves obtained in these two groups were compared using an F-test.
Results
We screened 49 individuals and excluded 6 (5 did not meet eligibility criteria; 1 withdrew prior to randomization). Of the 43 participants randomized, 7 (recruited consecutively) were excluded due to a technical problem with the MGIT cultures that invalidated the results (data for these 7 are not presented in this manuscript). The characteristics of the 36 evaluable participants (8 in the faropenem ! amoxicillin/clavulanic acid group, 14 in the rifampicin group and 14 in the rifampicin ! faropenem ! amoxicillin/clavulanic acid group) were similar between the three randomized groups [median age 33 years; median weight 68 kg; 30 (83%) male; 32 (89%) Chinese; 3 interferon-c release assay (IGRA) positive, one in each randomized group]. Study drugs were well tolerated with no adverse events.
The C max and AUC of faropenem were 5.4 mg/L and 16.2 mgÁh/L, respectively, in the faropenem ! amoxicillin/clavulanic acid group. There was no significant effect of coadministration of rifampicin on the PK of faropenem or amoxicillin, or vice versa (Table 1 and Figure S1 ).
In the faropenem ! amoxicillin/clavulanic acid group, mean WBA values were above zero (i.e. no bactericidal activity) at all individual timepoints through the 8 h post-dose measurement period (Figure 1a) . The mean maximal WBA activity was 0.07+0.13 Dlog cfu (P " 0.91 versus zero change; Table 2 ). The mean cumulative WBA at 8 h post-dose, the primary outcome, was 0.02+0.02 Dlog cfu (P " 0.99 versus zero change; Table 2 and Figure 1b ). There was no relationship between WBA and faropenem plasma concentrations (P " 0.449 for slope of regression line tested versus zero; Figure 2 ).
In the rifampicin and rifampicin ! faropenem ! amoxicillin/ clavulanic acid groups, mean WBA values were below zero throughout the 8 h post-dose measurement period (i.e. demonstrating bactericidal activity; Figure 1a) . The mean maximal WBA in the rifampicin and rifampicin ! faropenem ! amoxicillin/ clavulanic acid groups was similar (P " 0.56; Table 2 ). The Gurumurthy et al.
mean cumulative WBA suggested a trend in favour of the rifampicin ! faropenem ! amoxicillin/clavulanic acid group at 8 h postdose (#0.19+0.03 and #0.20+0.03 Dlog cfu in the rifampicin group and the rifampicin ! faropenem ! amoxicillin/clavulanic acid group, respectively; P " 0.180; Table 2 and Figure 1b) . The difference was statistically significant when the groups were compared over the first hour post-dose (P " 0.032; Table 2 and Figure 1b ). There was a clear relationship between WBA and rifampicin plasma concentrations measured in all individual samples, but the relationship was similar in the two groups (P " 0.575; Figure 3 ).
The proportion of the original drug concentration remaining at 24, 48 and 72 h after incubation of whole-blood samples at 37 C was 30%, 15% and ,2%, respectively, for faropenem, 60%, 40% and 20%, respectively, for amoxicillin and 80%, 60% and 40%, respectively, for rifampicin. There was no evidence of bactericidal activity when supplementary faropenem was added during the culture period (mean WBA 0.25+0.09 Dlog cfu).
The MIC 90 of faropenem for the Mtb H37Rv strain used in this study was 5-10 mg/L and the MBC 99 was 20 mg/L.
Discussion
We found that faropenem (administered with amoxicillin/clavulanic acid) had no bactericidal activity against Mtb H37Rv when given without other active TB drugs. Our findings agree with those of a 14 day EBA study of faropenem (given at the same dose, also with amoxicillin/clavulanic acid). 13 Testing drug activity in a WBA trial has some advantages over an EBA trial: it yields faster results, is more economical, is easier for participants and can be done in healthy volunteers (addressing theoretical concerns about the possibility of generating resistance with EBA monotherapy studies in TB patients, although this has rarely been demonstrated). The WBA assay tests activity of drugs against intracellular bacilli, which may be more representative of sterilizing activity (the most desirable property of new TB drugs as it relates to ultimate cure), whereas the main criticism of EBA is that it measures drug activity predominantly against extracellular organisms.
14 In spite of the differences in the two experimental paradigms, they have in the past generally yielded consistent answers when applied to testing different TB drugs, 15, 16 as in this case. The two approaches are complementary, and when results agree this gives greater confidence in the findings. Alternatively, WBA might be utilized to select drugs and doses that merit testing in a subsequent EBA study; in this case, an initial WBA study of faropenem might have obviated the need to perform an EBA study to address this study question.
The absence of faropenem bactericidal activity we observed may in part reflect insufficient drug levels achieved with the 600 mg oral dose (plasma C max was close to the MIC for the Mtb H37Rv strain used in this study). The C max was $20% lower than we had expected from the manufacturer's PK data, although it was higher than in the EBA study done in African TB patients. 6, 13 Drug levels present in the WBA assay were further reduced by the initial assay dilution step and the rapid degradation of faropenem in whole blood (unexpected, given the high stability of faropenem previously reported in aqueous solution 17 ), although these are unlikely to explain the outcome, as when we added supplementary faropenem at intervals to WBA cultures to restore levels close to plasma C max we still did not detect any bactericidal activity. Poor intracellular drug penetration, characteristic of some b-lactams, 18,19 also seems unlikely to represent a major impediment for this drug; faropenem has previously shown bactericidal 
Values shown are geometric mean and percentage coefficient of variation for AUC last and C max , median (minimum, maximum) for T max and mean (SD) for t 1/2 . PK parameters were compared between groups using a two-sided, two-sample t-test (log-transformed C max , log-transformed AUC last , t 1/2 ) or MannWhitney U-test (T max ).
Whole-blood bactericidal activity of faropenem with and without rifampicin JAC activity against Mtb in an intracellular macrophage model.
19,20
We did not find any indication of a concentration-activity relationship that might suggest the prospect of improved WBA if we were able to give a moderately higher dose of faropenem (the scope for dose increase is limited as we used the maximum licensed dose for this study). An alternative formulation, faropenem medoxomil (used in the early licensing studies) [21] [22] [23] [24] [25] produces approximately twice the plasma levels as the faropenem sodium formulation we used, but this formulation is no longer available. Given that data from clinical case series and EBA studies suggest a potential role Cumulative WBA at 8 h in the faropenem ! amoxicillin/clavulanic acid group was compared with zero using a one-sided, one-sample t-test. Cumulative WBA over the interval to 8 h was compared in the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups using a one-sided t-test (with a supplementary analysis comparing the groups on the cumulative WBA over the interval to 1 h post-dose). RIF, rifampicin; FAR, faropenem; AMC, amoxicillin/clavulanic acid.
for meropenem (and possibly imipenem) in the treatment of MDR TB (perhaps because with an intravenous formulation they can achieve much higher concentrations than faropenem in relation to their Mtb MIC), these appear more promising candidates to develop for the indication of MDR TB treatment. 26, 27 There is also a need to find ways of increasing the sterilizing efficacy of the standard combination for drug-susceptible TB, with a view to reducing treatment duration. For treatment of drugsusceptible TB, an oral drug is essential and hence faropenem has a clear advantage over intravenous carbapenems. Synergy between faropenem and rifampicin has previously been reported in an in vitro study. 7 Although visual inspection of the mean WBA, cumulative WBA and concentration-activity graphs suggests the possibility of enhanced activity with the combination, the difference was modest at best and, with the exception of an analysis of cumulative WBA within the first hour after dosing, was not statistically significant. Synergy may have been blunted by the same factors-low plasma levels, degradation in whole blood and uncertain intracellular penetration-that may have contributed to the absence of faropenem activity when used alone, as discussed above. It is also possible that in the WBA assay, where effects are dominated by the strong activity of rifampicin, which reaches a maximum at around 2 h after dosing and is then sustained over the 8 h post-dose period, there may be limited opportunity to demonstrate synergy. However, in clinical practice, where rifampicin is dosed once daily and its effects may wane towards the end of the dosing cycle, faropenem (dosed three or four times daily) might have a more meaningful effect in enhancing rifampicin activity (with potential for increased sterilizing activity over a treatment course). It is possible that other b-lactams may have greater synergistic effects than faropenem in this assay, as seen in in vitro studies. 8 In summary, we did not find evidence of bactericidal activity of faropenem given alone (without other TB drugs), possibly because plasma levels achieved were barely above the MIC. However, our findings lend modest support to the possibility of synergistic effects of faropenem that may merit further evaluation as a potential adjunct to standard rifampicin-containing TB therapy. In the faropenem ! amoxicillin/clavulanic acid group, maximum WBA and cumulative WBA were each compared with zero using a one-sided, one-sample t-test.
Maximum WBA and cumulative WBA of the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups were compared using a one-sided t-test.
Whole-blood bactericidal activity of faropenem with and without rifampicin Relationship between rifampicin plasma concentration and WBA in the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups. Each point represents an individual blood sample for which both parameters were measured. The relationship between rifampicin plasma concentration and WBA in the rifampicin and rifampicin ! faropenem ! amoxicillin/clavulanic acid groups was determined separately for each group by non-linear regression performed using a four-parameter equation to describe a sigmoid curve and equation parameters were fitted to observed values by iterative methods using SAS. The curves obtained in these two groups were compared using an F-test. RIF, rifampicin; FAR, faropenem; AMC, amoxicillin/clavulanic acid.
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